Clinical trials: Plaque Psoriasis.
Psoriasis
Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab
The purpose of this study was to explore the effect of treatment with 300 mg or with 150 mg secukinumab (administered weekly for 4 weeks followed by four-weekly administration) on endothelial dysfunction and arterial stiffness…
- Trial name
- CARIMA (NCT02559622)
- Testing
- Secukinumab
- Where
- 23 sites in Germany
- Volunteers
- 151 people
- Sponsor
- Novartis Pharmaceuticals
Pruritus, Psoriasis
Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Plaque Psoriasis
Study of the efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in adults with plaque psoriasis
- Trial name
- NCT03343639
- Testing
- 5 mg Serlopitant Tablets
- Where
- 39 sites in United States
- Volunteers
- 204 people
- Sponsor
- Vyne Therapeutics Inc.
Psoriasis
A Study of Guselkumab (TREMFYA) in Chinese Participants With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the efficacy, safety and tolerability of guselkumab in the treatment of Chinese participants with moderate to severe plaque psoriasis.
- Trial name
- NCT04914429
- Testing
- Guselkumab
- Where
- 26 sites in China
- Volunteers
- 327 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis
BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
This is a randomized double blind, double dummy, placebo and active comparator controlled, parallel design study that is being performed to assess the safety and efficacy of risankizumab (BI 655066) to support registration for…
- Trial name
- NCT02684357
- Testing
- risankizumab, ustekinumab
- Volunteers
- 577 people
- Sponsor
- AbbVie
Plaque Psoriasis
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
The purpose of the study is to see how effective JNJ-77242113 is in participants with plaque psoriasis affecting special areas (scalp, genital, and/or palms of the hands and the soles of the feet).
- Trial name
- ICONIC-TOTAL (NCT06095102)
- Testing
- JNJ-77242113
- Where
- 90 sites in United States, Argentina and 9 more
- Volunteers
- 311 people
- Sponsor
- Janssen Research & Development, LLC
Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis
This is a randomized, double-blind, placebo-controlled, multi-center Phase 2 study to evaluate the efficacy and safety of HB0017 in subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT05531682
- Testing
- HB0017
- Where
- 21 sites in China
- Volunteers
- 160 people
- Sponsor
- Huabo Biopharm Co., Ltd.
Psoriasis, Obesity
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and…
- Trial name
- TOGETHER-PsO (NCT06588283)
- Testing
- Ixekizumab, Tirzepatide
- Where
- 72 sites in United States, Puerto Rico
- Volunteers
- 281 people
- Sponsor
- Eli Lilly and Company
Chronic Plaque-type Psoriasis
Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis
A randomized, double-blind, placebo and positive controlled, single and multiple dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of CJM112 in chronic plaque-type psoriasis patients.
- Trial name
- NCT01828086
- Testing
- CJM112, Secukinumab
- Where
- 18 sites in United States
- Volunteers
- 95 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis
Hemay005 is a novel phosphodiesterase type 4(PDE4) inhibitor being developed for the treatment of psoriasis.After single asending dose and mutiple asending dose in health subjects.
- Trial name
- NCT04102241
- Testing
- 15mg Hemay005
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
Psoriasis, Plaque-type Psoriasis
Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)
The purpose of this study was to test if the drug apremilast was safe, if it helped improve psoriasis, and how well the participants tolerated it.
- Trial name
- NCT00773734
- Testing
- Apremilast 10mg, Apremilast 20mg, Apremilast 30 mg
- Where
- 35 sites in United States, Canada
- Volunteers
- 352 people
- Sponsor
- Amgen
Moderate to Severe Plaque Psoriasis
A Phase 4 Study of Brodalumab (KHK4827) in Subjects With Moderate to Severe Plaque Psoriasis
The objective of this study is assessing the efficacy and safety of brodalumab in Chinese subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT04614298
- Testing
- KHK4827-Active
- Where
- 25 sites in China
- Sponsor
- Kyowa Kirin Co., Ltd.
Psoriasis
A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis
This multicenter study is being conducted to provide additional PF-06826647 safety and tolerability data, and to further explore the clinical efficacy of PF-06826647 in the treatment of moderate to severe plaque psoriasis.
- Trial name
- NCT03895372
- Testing
- PF-06826647
- Where
- 45 sites in United States, Canada and 2 more
- Volunteers
- 179 people
- Sponsor
- Pfizer
Psoriasis
A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01309737
- Testing
- CP-690,550
- Where
- 94 sites in United States, Canada and 9 more
- Volunteers
- 960 people
- Sponsor
- Pfizer
Chronic Plaque Psoriasis
A Multicenter Study to Evaluate the Safety and Tolerability of Single-Dose for MEDI-545
-To evaluate the safety and tolerability of a multiple doses of this drug in adult patients.
- Trial name
- CP145 (NCT00472758)
- Testing
- MEDI 545
- Where
- 3 sites in Canada
- Volunteers
- 40 people
- Sponsor
- MedImmune LLC
Moderate to Severe Plaque Psoriasis
Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Compare the efficacy of ABT-874 versus etanercept in subjects with moderate to severe plaque psoriasis
- Trial name
- NCT00710580
- Testing
- ABT-874, etanercept
- Where
- 42 sites in United States
- Volunteers
- 350 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Moderate to Severe Plaque Psoriasis
Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque Psoriasis
To determine whether secukinumab can alter the activity of cytochrome P450 (CYP) 3A4 using midazolam as probe substrate in patients with moderate-to-severe plaque psoriasis.
- Trial name
- NCT02607774
- Testing
- Midazolam, AIN457
- Where
- 8 sites in United States
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis in Children, Plaque Psoriasis in Adolescents
A Clinical Study to Evaluate the Safety and Pharmacokinetics of Topical RSS0393 Ointment in Children and Adolescents With Plaque Psoriasis
This study is to evaluate the safety, tolerability, pharmacokinetics and efficacy of RSS0393 topical ointment in the treatment of plaque psoriasis in children and adolescents.
- Trial name
- NCT07102888
- Testing
- RSS0393 Ointment
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Parapsoriasis, Healthy Volunteers
Phase 1 Study of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis
To evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of CC-90005 in healthy subjects and subjects with moderate to severe plaque-type psoriasis.
- Trial name
- NCT02502188
- Testing
- CC-90005
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Celgene
Plaque Psoriasis
Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis
There are cells in the skin and blood of humans with chronic moderate to severe plaque psoriasis with specific activities that may determine the effectiveness of treatment.
- Trial name
- NCT01710046
- Testing
- (CP-6890,550) Tofacitinib, (CP-690,550) Tofacitinib
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Pfizer
Psoriasis
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin.
- Trial name
- OptIMMize-2 (NCT04862286)
- Testing
- Risankizumab
- Where
- 41 sites in United States, Canada and 5 more
- Volunteers
- 132 people
- Sponsor
- AbbVie